KPC Pharmaceuticals,Inc., a pharmaceutical company, (600422) Fair Value & Analysis
Healthcare · CN · Market cap 6.4B CNY
Analysis
KPC Pharmaceuticals,Inc., a pharmaceutical company, (600422) currently trades at ¥8.03, while our model-based Fair Value estimate is ¥8.68 — implying the stock looks roughly 8.1% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People's Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, comether tablets, specialty herbal products, classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections, and other products, as well as engages in the wholesale and retail of medicines and equipment. The company offers products in the field of cardiovascular and cerebrovascular, orthopedics series, antimalarial, gynecology, digestive system, and others treatments. It offers its products under Luotai, Tianxuanqing, Artemedine, Artem, and Arco brands. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. KPC Pharmaceuticals,Inc. was founded in 1951 and is based i…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.